Show simple item record

dc.contributor.authorEvangelidis, Nicole
dc.contributor.authorTong, Allison
dc.contributor.authorHowell, Martin
dc.contributor.authorTeixeira-Pinto, Armando
dc.contributor.authorElliott, Julian H
dc.contributor.authorAzevedo, Luciano Cesar
dc.contributor.authorBersten, Andrew
dc.contributor.authorCervantes, Lilia
dc.contributor.authorChew, Derek P
dc.contributor.authorCrowe, Sally
dc.contributor.authorDouglas, Ivor S
dc.contributor.authorFlemyng, Ella
dc.contributor.authorHorby, Peter
dc.contributor.authorLee, Jaehee
dc.contributor.authorLorca, Eduardo
dc.contributor.authorLynch, Deena
dc.contributor.authorMarshall, John C
dc.contributor.authorMcKenzie, Anne
dc.contributor.authorMehta, Sangeeta
dc.contributor.authorMer, Mervyn
dc.contributor.authorMorris, Andrew Conway
dc.contributor.authorNseir, Saad
dc.contributor.authorPovoa, Pedro
dc.contributor.authorReid, Mark
dc.contributor.authorSakr, Yasser
dc.contributor.authorShen, Ning
dc.contributor.authorSmyth, Alan R
dc.contributor.authorSnelling, Tom
dc.contributor.authorStrippoli, Giovanni FM
dc.contributor.authorTorres, Antoni
dc.contributor.authorTurner, Tari
dc.contributor.authorWebb, Steve
dc.contributor.authorWilliamson, Paula R
dc.contributor.authorWoc-Colburn, Laila
dc.contributor.authorZhang, Junhua
dc.contributor.authorBaumgart, Amanda
dc.contributor.authorCabrera, Sebastian
dc.contributor.authorCho, Yeoungjee
dc.contributor.authorCooper, Tess
dc.contributor.authorGuha, Chandana
dc.contributor.authorLiu, Emma
dc.contributor.authorGonzalez, Andrea Matus
dc.contributor.authorMcLeod, Charlie
dc.contributor.authorNatale, Patrizia
dc.contributor.authorSaglimbene, Valeria
dc.contributor.authorViecelli, Andrea K
dc.contributor.authorCraig, Jonathan C
dc.contributor.authorCOVID-19-Core Outcomes Set (COS) Survey Investigators
dc.description.abstractOBJECTIVES: There are over 4,000 trials conducted in people with coronavirus disease 2019. However, the variability of outcomes and the omission of patient-centered outcomes may diminish the impact of these trials on decision-making. The aim of this study was to generate a consensus-based, prioritized list of outcomes for coronavirus disease 2019 trials. DESIGN: In an online survey conducted in English, Chinese, Italian, Portuguese, and Spanish languages, adults with coronavirus disease 2019, their family members, health professionals, and the general public rated the importance of outcomes using a 9-point Likert scale (7-9, critical importance) and completed a Best-Worst Scale to estimate relative importance. Participant comments were analyzed thematically. SETTING: International. SUBJECTS: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public, and health professionals (including clinicians, policy makers, regulators, funders, and researchers). INTERVENTIONS: None. MEASUREMENTS: None. MAIN RESULTS: In total, 9,289 participants from 111 countries (776 people with coronavirus disease 2019 or family members, 4,882 health professionals, and 3,631 members of the public) completed the survey. The four outcomes of highest priority for all three groups were: mortality, respiratory failure, pneumonia, and organ failure. Lung function, lung scarring, sepsis, shortness of breath, and oxygen level in the blood were common to the top 10 outcomes across all three groups (mean > 7.5, median ≥ 8, and > 70% of respondents rated the outcome as critically important). Patients/family members rated fatigue, anxiety, chest pain, muscle pain, gastrointestinal problems, and cardiovascular disease higher than health professionals. Four themes underpinned prioritization: fear of life-threatening, debilitating, and permanent consequences; addressing knowledge gaps; enabling preparedness and planning; and tolerable or infrequent outcomes. CONCLUSIONS: Life-threatening respiratory and other organ outcomes were consistently highly prioritized by all stakeholder groups. Patients/family members gave higher priority to many patient-reported outcomes compared with health professionals.
dc.description.sponsorshipThe project is funded by the Flinders University and the National COVID-19 Clinical Evidence Taskforce, convened by the Australian Living Evidence Consortium, hosted by Cochrane Australia, School of Public Health and Preventive Medicine, Monash University supported by the Australian Government, Victorian Department of Health and Human Services, Ian Potter Foundation, Walter Cottman Endowment Fund (managed by Equity Trustees) and the Lord Mayor's Charitable Foundation). AT is supported by The University of Sydney Robinson Fellowship. ACM is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z)
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.rightsAttribution 4.0 International (CC BY)
dc.subjectCOVID-19-Core Outcomes Set (COS) Survey Investigators
dc.subjectPneumonia, Viral
dc.subjectCoronavirus Infections
dc.subjectResearch Design
dc.subjectMiddle Aged
dc.subjectHealth Priorities
dc.subjectHealth Services Accessibility
dc.subjectRandomized Controlled Trials as Topic
dc.subjectSymptom Assessment
dc.subjectOutcome Assessment, Health Care
dc.titleInternational Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019.
prism.publicationNameCrit Care Med
dc.contributor.orcidTeixeira-Pinto, Armando [0000-0002-9389-2516]
dc.contributor.orcidFlemyng, Ella [0000-0002-9845-9076]
dc.contributor.orcidSmyth, Alan R [0000-0001-5494-5438]
dc.contributor.orcidSnelling, Tom [0000-0003-4670-0638]
dc.contributor.orcidMcLeod, Charlie [0000-0002-3197-7493]
rioxxterms.typeJournal Article/Review
pubs.funder-project-idWellcome Trust (205214/Z/16/Z)
cam.orpheus.successTue Sep 01 14:00:05 BST 2020 - Embargo updated

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY)